Corporate Profile

PrintBio is a privately held, clinical- and commercial-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and material science technologies to deliver safe, functional and personalized products and living tissues and organs, engineered and produced on-demand for patients. The Company was founded and is led by an experienced team of biotechnology founders and executives.

For questions regarding investment opportunities, email: investors@printbio.com

Recent Updates

PrintBio Receives FDA Clearance for 3DMatrix DynaFlex™, Adding Uniflex™ Technology to 3DMatrix™, the First 3D-Printed Resorbable Surgical Mesh Approved Less than One Year Ago

egalli | News, Press Releases | No Comments

3DMatrix DynaFlex™ incorporates PrintBio’s proprietary Uniflex™ unidirectional flexible mesh technology PrintBio was founded by Rapha Capital Management, LLC and its investors through its SPV, Rapha Capital Investment XIV, LLC MIAMI,…

Brent Saunders Appointed as Advisory Board Chairman

egalli | News, Press Releases | No Comments

Saunders was previously CEO of Allergan, the company that developed and launched Botox™ until the company’s $63 billion acquisition by AbbVie Inc. in 2020 Miami, FL – February 26, 2025…

PrintBio Receives FDA Clearance for 3DMatrix™, the First 3D-Printed Resorbable Surgical Mesh

egalli | News, Press Releases | No Comments

PrintBio Receives FDA Clearance for 3DMatrix™, the First 3D-Printed Resorbable Surgical Mesh PrintBio was founded by Rapha Capital Management, LLC and its investors through its SPV, Rapha Capital Investment XIV,…

View All